Cohance Lifesciences has announced its unaudited financial results for the quarter and half-year ended 30 September 2026. The Board of Directors also approved the appointment of Dr. Kuber Jagdale as Additional Director, designated as Chief Technical Officer & Executive Director for a period of 5 years. Additionally, the company plans an equity investment of 26% in a Special Purpose Vehicle (SPV) for solar power generation.
Cohance Lifesciences Board Approves Financial Results and Key Appointments
Mumbai, 6 November 2026 – Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) announced today the outcome of its Board of Directors’ meeting held on 6 November 2026. The Board approved the unaudited standalone and consolidated financial results for the Quarter and Half year ended 30 September 2026.
Key Financial Highlights:
The financial results for the period revealed performance metrics across various segments. The company reported a revenue of INR 4,766 Mn for Q2FY27, a 12.9% sequential growth. Adjusted EBITDA stood at INR 459 Mn, with margins at 10%. For the half-year ended 30 September 2026, revenue was INR 8,989 Mn, with Adjusted EBITDA at INR 551 Mn and margins at 6.1%. The consolidated financial statements also detailed movements in assets, liabilities, and cash flows, indicating a net cash position of INR 666 Mn as of 30 September 2026.
Strategic Appointments and Investments:
In a significant move to strengthen its leadership and technical expertise, the Board appointed Dr. Kuber Jagdale (DIN: 12037580) as an Additional Director, designated as Chief Technical Officer & Executive Director. This appointment is effective from 7 November 2026 for a term of 5 years, subject to shareholder approval. Dr. Jagdale brings over three decades of experience in the pharmaceutical industry.
Furthermore, the company approved a proposed equity investment of 26% in a Special Purpose Vehicle (SPV) that is being incorporated for solar power generation. This initiative aims to secure captive power for Cohance’s plant operations, achieve Green Industry status, and transition towards sustainable energy sources, with projected savings via tariff and CO2 emissions reduction.
Operational and Business Updates:
The investor presentation provided insights into the company’s performance, highlighting sequential revenue growth in Q2 FY27 and improved EBITDA margins. Strategic progress was noted in the integration of the ‘One Cohance’ platform across businesses. The Pharma CDMO segment, particularly Small Molecules and Nucleic Acid business, showed positive developments. The company anticipates a stronger H2 FY27, driven by continued recovery and progressive integration of capabilities.
Auditor’s Review:
The financial results have undergone a limited review by statutory auditors, Walker Chandiok & Co LLP, who expressed an unmodified conclusion. The review reports for both standalone and consolidated financial results confirmed that the statements are prepared in accordance with applicable accounting standards and regulatory requirements, and no material misstatements were identified.
Source: BSE
